直立性低血壓藥物市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、診斷測試類型、最終用戶、地區和競爭細分，2020-2030 年）

2024 年全球直立性低血壓藥物市場價值為 5.4226 億美元，預計到 2030 年將以 8.26% 的複合年成長率成長。直立性低血壓或姿勢性低血壓是指站立時血壓突然下降，導致頭暈、昏厥和疲勞等症狀。雖然這種情況通常是暫時的，但也可能表明更嚴重的潛在健康問題，尤其是對於老年人或高血壓患者。市場受益於人們意識的不斷增強（尤其是老齡化人口）和診斷能力的提高。臨床工具和診斷協議的創新（例如動態血壓監測）有助於及時發現和治療。此外，人們越來越關注老年人和高血壓患者中直立性低血壓的盛行率，特別是在發展中地區，這刺激了對旨在改善患者預後和降低心血管風險的有效藥物療法的需求。

關鍵市場促進因素

醫學診斷的進步

主要市場挑戰

合併症和複雜的患者情況

主要市場趨勢

神經源性直立性低血壓（nOH）焦點

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球直立性低血壓藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 副產物（屈昔多巴、氟氫可的松、吲哚美辛、鹽酸米多君、非類固醇抗發炎藥、吡斯的明）
  • 依診斷測試類型（血液檢查、心電圖、超音波心動圖、壓力測試）
  • 按最終使用者（門診手術中心、診斷中心、醫院和診所）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：亞太地區直立性低血壓藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第7章：歐洲直立性低血壓藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第8章：北美直立性低血壓藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第9章：南美洲直立性低血壓藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲直立性低血壓藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球直立性低血壓藥物市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Mylan NV
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

第 17 章：策略建議

第18章調查會社について,免責事項

The Global Orthostatic Hypotension Drugs Market was valued at USD 542.26 million in 2024 and is projected to grow at a CAGR of 8.26% through 2030. Orthostatic hypotension, or postural hypotension, involves a sudden drop in blood pressure upon standing, leading to symptoms such as dizziness, fainting, and fatigue. While often transient, the condition can also indicate more serious underlying health issues, especially in older or hypertensive individuals. The market benefits from growing awareness, especially among aging populations, and improved diagnostic capabilities. Innovations in clinical tools and diagnostic protocols-such as dynamic blood pressure monitoring-are facilitating timely detection and treatment. Additionally, rising attention to orthostatic hypotension's prevalence among elderly and hypertensive patients, particularly in developing regions, is spurring demand for effective pharmaceutical therapies aimed at improving patient outcomes and reducing cardiovascular risk.

Key Market Drivers

Advancements in Medical Diagnostics

Medical diagnostics have seen transformative progress, significantly influencing the management of orthostatic hypotension. Advanced molecular tools such as PCR, next-generation sequencing, and gene profiling now enable precise disease detection and characterization. Liquid biopsies offer a non-invasive method for monitoring disease biomarkers, aiding early diagnosis and treatment response. Additionally, point-of-care devices have become more efficient, providing rapid results critical for conditions like blood pressure abnormalities. Imaging advancements-including MRI, CT, and PET-further improve disease visualization and understanding. Artificial intelligence is increasingly applied to analyze complex datasets, supporting diagnostic accuracy and treatment planning. Omics-based biomarker discovery is fostering new diagnostic tests for cardiovascular and neurodegenerative diseases. Notably, a 2024 statement by the American Heart Association emphasized improved diagnosis and management strategies for orthostatic hypotension in hypertensive patients, highlighting the growing clinical focus on this condition and the need for targeted therapies to enhance patient outcomes

Key Market Challenges

Comorbidities and Complex Patient Profiles

Managing orthostatic hypotension becomes increasingly difficult in patients with multiple coexisting conditions such as diabetes, hypertension, or cardiovascular disease. Many of these individuals are on complex medication regimens, increasing the risk of adverse drug interactions and complicating treatment decisions. Polypharmacy often undermines the effectiveness of orthostatic hypotension drugs and raises safety concerns. Customized treatment approaches are necessary to address each patient's unique health profile, which may demand frequent monitoring and ongoing adjustments to therapy. Additionally, patients with overlapping conditions like neurodegenerative disorders face an elevated risk of falls, requiring holistic care strategies. Understanding the complex interplay between various diseases and their impact on blood pressure regulation is vital to delivering effective and safe treatment solutions.

Key Market Trends

Neurogenic Orthostatic Hypotension (nOH) Focus

There is growing clinical and commercial interest in neurogenic orthostatic hypotension (nOH) as a distinct subset of the broader condition. Common in patients with neurological disorders, nOH is increasingly recognized due to improved diagnostic awareness and specialized testing. This subtype, typically involving impaired norepinephrine release, has prompted the development of targeted therapies aimed at improving blood pressure stability. Ongoing clinical trials are evaluating nOH-specific treatments, contributing to a robust pipeline of potential new therapies. Patient advocacy groups and neurological foundations are helping raise awareness and accelerate research in this space. Personalized care strategies are being adopted to address the unique clinical needs of nOH patients. Furthermore, diagnostic advances-such as autonomic function testing-are enhancing accuracy and supporting precision treatment. Pharmaceutical companies are investing in innovative drug classes, including norepinephrine prodrugs and reuptake inhibitors, to meet the specific demands of this growing patient population.

Key Market Players

• Mylan N.V.
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

Report Scope:

In this report, the Global Orthostatic Hypotension Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orthostatic Hypotension Drugs Market, By Product:

• Droxidopa
• Fludrocortisone
• Indomethacin
• Midodrine Hydrochloride
• NSAIDs
• Pyridostigmine

Orthostatic Hypotension Drugs Market, By Diagnostics Test Type:

• Blood Tests
• ECG
• Echocardiogram
• Stress Test

Orthostatic Hypotension Drugs Market, By End-User:

• Ambulatory Surgical Centers
• Clinics & Hospitals
• Diagnostic Centers

Orthostatic Hypotension Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orthostatic Hypotension Drugs Market.

Available Customizations:

Global Orthostatic Hypotension Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orthostatic Hypotension Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Droxidopa, Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, Pyridostigmine)
  • 5.2.2. By Diagnostics Test Type (Blood Tests, ECG, Echocardiogram, Stress Test)
  • 5.2.3. By End User (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Orthostatic Hypotension Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Diagnostics Test Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Orthostatic Hypotension Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Diagnostics Test Type
      • 6.3.1.2.3. By End User
  • 6.3.2. India Orthostatic Hypotension Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Diagnostics Test Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Orthostatic Hypotension Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Diagnostics Test Type
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Orthostatic Hypotension Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Diagnostics Test Type
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Orthostatic Hypotension Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Diagnostics Test Type
      • 6.3.5.2.3. By End User

7. Europe Orthostatic Hypotension Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Diagnostics Test Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Orthostatic Hypotension Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Diagnostics Test Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Orthostatic Hypotension Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Diagnostics Test Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Orthostatic Hypotension Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Diagnostics Test Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Orthostatic Hypotension Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Diagnostics Test Type
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Orthostatic Hypotension Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Diagnostics Test Type
      • 7.3.5.2.3. By End User

8. North America Orthostatic Hypotension Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Diagnostics Test Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Orthostatic Hypotension Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Diagnostics Test Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Orthostatic Hypotension Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Diagnostics Test Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Orthostatic Hypotension Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Diagnostics Test Type
      • 8.3.3.2.3. By End User

9. South America Orthostatic Hypotension Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Diagnostics Test Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Orthostatic Hypotension Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Diagnostics Test Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Orthostatic Hypotension Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Diagnostics Test Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Orthostatic Hypotension Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Diagnostics Test Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Orthostatic Hypotension Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Diagnostics Test Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Orthostatic Hypotension Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Diagnostics Test Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Orthostatic Hypotension Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Diagnostics Test Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Orthostatic Hypotension Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Diagnostics Test Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Orthostatic Hypotension Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Mylan N.V.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Upsher-Smith Laboratories, LLC
• 16.3. Chelsea Therapeutics International, Ltd
• 16.4. Amgen Inc
• 16.5. F. Hoffmann-La Roche Ltd
• 16.6. Apotex Inc
• 16.7. Pfizer Inc.
• 16.8. Novartis AG
• 16.9. H. Lundbeck A/S
• 16.10. Amneal Pharmaceuticals LLC

17. Strategic Recommendations

18. About Us & Disclaimer